Skip to main content
SpringerLink
Log in
Book cover

Discussing Migraine With Your Patients pp 113–133Cite as

When, How Much, and How Often

  • Chapter
  • First Online:

  • 766 Accesses

Abstract

Medications have an important role in migraine management. It is important to understand the distinct role and limitations in migraine prevention, acute treatment, and rescue. Prevention should be started when migraine has an intolerable effect on functioning. Acute medication use should be focused on restoring function, but their use also needs to be limited because of the propensity to induce migraine progression. The frequent use of both acute and rescue medications indicate that prevention should have an increasingly prominent role. Successful migraine management will always include an acute treatment plan and a rescue plan, and frequently a preventive plan.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Pracilio VP, Silberstein S, Couto J, Bumbaugh J, Hopkins M, Ng-Mak D, et al. Measuring migraine-related quality of care across 10 health plans. Am J Manag Care. 2012;18:e291–9.

    PubMed  Google Scholar 

  2. Muzina DJ, Chen W, Bowlin SJ. A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns. Neuropsychiatr Dis Treat. 2011;7:663–72.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Wu J, Hughes MD, Hudson MF, Wagner PJ. Antimigraine medication use and associated health care costs in employed patients. J Headache Pain. 2012;13:121–7.

    Article  PubMed  Google Scholar 

  4. Silberstein SD, Marcus DA. Sumatriptan: treatment across the full spectrum of migraine. Expert Opin Pharmacother. 2013;14:1659–67.

    Article  CAS  PubMed  Google Scholar 

  5. Obaidi M, Offman E, Messina J, Carothers J, Djupesland PG, Mahmoud RA. Improved pharmacokinetics of sumatriptan with breath powered™ nasal delivery of sumatriptan powder. Headache. 2013;53:1323–33.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wertz DA, Quimbo RM, Yaldo AZ, Rupnow MF. Resource utilization impact of topiramate for migraine prevention in the managed-care setting. Curr Med Res Opin. 2009;25:499–503.

    Article  CAS  PubMed  Google Scholar 

  7. Evers S. Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother. 2008;9:2565–73.

    Article  CAS  PubMed  Google Scholar 

  8. Silberstein SD, Holland S, Frietag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. 2012;78:1346–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Peres MF, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N, et al. Patients’ preferences for migraine prevention therapy. Headache. 2007;47:540–5.

    Article  PubMed  Google Scholar 

  11. von Peter S, Ting W, Scrivani S, Korkin E, Okvat H, Gross M, et al. Survey on the use of complementary and alternative medicine among patients with headache syndromes. Cephalalgia. 2002;22:395–400.

    Article  Google Scholar 

  12. Lambert TD, Morrison KE, Edwards J, Clarke CE. The use of complementary and alternative medicine by patients attending a UK headache clinic. Complement Ther Med. 2010;18:128–34.

    Article  PubMed  Google Scholar 

  13. Cascussi G, Cevoli S. Controversies in migraine treatment: opioids should be avoided. Neurol Sci. 2013;34 Suppl 1:S125–8.

    Google Scholar 

  14. Raffa RB, Pergolizzi JV. Opioid-induced hyperalgesia: is it clinically relevant for the treatment of pain patients? Pain Manag Nurs. 2013;14:e67–83.

    Article  PubMed  Google Scholar 

  15. Tfelt-Hansen PC, Diener H. Why should American headache and migraine patients still be treated with butalbital-containing medicine? Headache. 2012;54:672–4.

    Article  Google Scholar 

  16. Schulman EA, Lake AE, Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American Headache Society. Headache. 2008;48:778–82.

    Article  PubMed  Google Scholar 

  17. Pascual J. Clinical benefits of early triptan therapy for migraine. Headache. 2002;42 Suppl 1:10–7.

    Article  PubMed  Google Scholar 

  18. Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33:891–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pittsburgh, Pittsburgh, PA, USA

    Dawn A. Marcus MD

  2. Fellow American Headache Society, Temple, TX, USA

    Duren Michael Ready MD

Authors
  1. Dawn A. Marcus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Duren Michael Ready MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this chapter

Cite this chapter

Marcus, D.A., Ready, D.M. (2017). When, How Much, and How Often. In: Discussing Migraine With Your Patients. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-6484-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6484-0_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-6482-6

  • Online ISBN: 978-1-4939-6484-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation